On November 12, 2025, Vietnam's Ministry of Health delivered a significant milestone in the country's regulatory landscape for pharmaceuticals with the official market authorisation of Pembroria—a Russian-manufactured anti-cancer drug containing the active ingredient pembrolizumab—alongside 13 other vaccines and biological products. Under Decision No. 628/QĐ-QLD, issued by Director Vũ Tuấn Cường of the Drug Administration of Vietnam (DAV), these 14 biologics have been approved for a three-year circulation term as part of the ministry's comprehensive 57th registration round. This landmark development underscores Vietnam's ongoing drive to broaden access to innovative oncology therapies while tightening controls on biologics supply, manufacturing compliance, and real-world evidence reporting from strategic international partners.

Pembroria, produced by Russian pharmaceutical entity Limited Liability “PK-137” and registered through a UAE-based firm, contains pembrolizumab at a dosage of 100mg/4ml, formulated as a concentrated intravenous infusion, with a 24-month shelf life. Pembrolizumab, a high-value monoclonal antibody, is indicated for the management of over 14 cancer types, including but not limited to lung carcinoma, melanoma, colorectal cancer, cervical cancer, renal cell carcinoma, and breast cancer. Designed for deployment in the rapidly evolving treatment landscape of Vietnam, this approval addresses the severe and growing oncology burden reported by GLOBOCAN 2022, which estimated 180,480 new cancer cases and 120,184 cancer-related deaths nationwide, identifying breast, liver, lung, and colorectal cancers as the most prevalent.

The integration of pembrolizumab into Vietnam’s official formulary marks a vital step in technology transfer and market expansion from Eurasian producers into Southeast Asia, while catalyzing competition and local sector innovation. With treatment options in Vietnam spanning surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy—and demand for next-generation drugs like pembrolizumab surging—this authorisation represents a strategic milestone at the intersection of importation, local distribution, and technology-enabled care pathways. For multinational pharmaceutical manufacturers, contract research organisations (CROs), and logistics partners, the approval process sets a precedent for compliance and rapid entry of novel anticancer agents into Vietnam’s burgeoning market.

Vietnam’s regulatory framework mandating Good Manufacturing Practices (GMP) adherence remains central. Manufacturers and registration holders must ensure conformity of drug production and distribution with approved dossiers. If a manufacturer’s production license or GMP certificate is revoked by its home authority, prompt notification (within 15 days) and coordinated response with Vietnamese regulators are mandatory. Additionally, the ministry requires robust pharmacovigilance and data reporting protocols: registrants must supply quarterly updates on ongoing phase III immunogenicity studies for their products and submit supplementary data post-completion. These stipulations demonstrate the ministry’s focus on not only supply chain robustness but also real-world evidence and patient outcome data generation—a trend closely watched by pharmaceutical R&D and regulatory affairs teams across the region.

For local cancer care providers and CROs, the regulatory nod to Pembroria paves the way for rapid clinical integration. K (Cancer) Hospital’s Director Prof. Dr. Lê Văn Quảng indicated imminent adoption of the drug, although it is not yet insured under Vietnam’s national health system. From a market access and reimbursement perspective, this highlights ongoing opportunities and challenges linked to high-cost biologics in emerging Asian markets. Pembroria’s current price is approximately VNĐ18 million (USD 580) per vial, with standard regimens requiring two vials per treatment cycle—a significant expenditure for Vietnamese patients and a key focus for future payer and government negotiations.

Strategically, this latest regulatory authorisation round also included biopharmaceuticals for treating stroke, lupus, osteoporosis, skin conditions, rheumatoid arthritis, ankylosing spondylitis, blood disorders, and multiple sclerosis, reflecting Vietnam’s widening acceptance of innovative and complex global therapies. For industry stakeholders—especially those in pharmaceutical supply chain solutions, analytics, contract manufacturing, and compliance technology—this move signals growing demand for internationally accredited products, third-party logistic support, and tailored commercial models.

The Vietnamese health authorities’ comprehensive approach exemplifies rising regulatory sophistication and alignment with international GMP, pharmacovigilance, and real-world evidence standards in Asia. This both challenges and incentivizes CRO, manufacturing, and supply partners to elevate operational transparency, compliance infrastructure, and data management capabilities across the value chain. As digital systems and automation increasingly integrate with regulatory monitoring, the bar for international market entry will continue rising, fostering greater pharmaceutical investment and partnership opportunities regionally.